title: In vivo T-cell depletion with low-dose ATG is effective in reducing cGVHD after peripheral blood stem cell myeloablative sibling transplants in CML: results from a prospective phase II study.
authors.forename: F
authors.initials: F
authors.lastname: Bonifazi
authors.forename: G
authors.initials: G
authors.lastname: Bandini
authors.forename: M
authors.initials: M
authors.lastname: Stanzani
authors.forename: F
authors.initials: F
authors.lastname: Palandri
authors.forename: B
authors.initials: B
authors.lastname: Giannini
authors.forename: M
authors.initials: M
authors.lastname: Arpinati
authors.forename: G
authors.initials: G
authors.lastname: Rosti
authors.forename: M
authors.initials: M
authors.lastname: Baccarani
mesh_terms: D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D002908:Chronic Disease; D006086:Graft vs Host Disease / Q000517:prevention & control*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D008212:Lymphocyte Depletion; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D011446:Prospective Studies
chemical_list: D000961:Antilymphocyte Serum